Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-Blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC).

Next Previous
X
Search
Trial Profile

A Phase II, Double-Blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary) ; Docetaxel; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004144).
    • 14 Apr 2009 Actual end date changed from Nov 2006 to Sep 2008 as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Primary endpoint 'Prostate specific antigen response rate' has not been met according to results published in Cancer Biotherapy and Radiopharmaceuticals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top